Notably, the SARC006 trial, which tested the effect of the TOP2A inhibitors doxorubicin and etoposide in combination with ifosfamide, reported an overall response rate of 33% in the sporadic and 17% in NF1‐associated MPNST, respectively, although both were below the set target of 40% (Widemann et al., 2013). The gene discussed is TOP2A; the disease is malignant peripheral nerve sheath tumor.